Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0D9LB
|
|||
| Former ID |
DCL000316
|
|||
| Drug Name |
BIBV 308
|
|||
| Synonyms |
Terbogrel; UNII-5Z4KWQ5OGN; 149979-74-8; 5Z4KWQ5OGN; CHEMBL281398; Terbogrel [USAN:INN]; BIBV 308 SE; Terbogrel (USAN/INN); AC1O6AAX; SCHEMBL42848; BIBV-308-SE; SCHEMBL15413063; ZINC11726169; BDBM50075624; DB12204; CS-6743; (5E)-6-(m-(3-tert-Butyl-2-cyanoguanidino)phenyl)-6-(3-pyridyl)-5-hexenoic acid; 6-(3-(((Cyanoamino)((1,1-dimethylethyl)amino)methylene)amino)phenyl)-6-(3-pyridinyl)hexenoic acid; HY-19189; D06077; L001474; 6-{3-[1-(tert-butylamino)-2-cyano-(E)-1-iminomethylamino]phenyl}-6-(3-pyridyl)-(E)-5-hexenoic acid
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Peripheral vascular disease [ICD-11: BD4Z; ICD-10: I73.9; ICD-9: 443.9] | Phase 1 | [1] | |
| Company |
Boehringer Ingelheim
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H27N5O2
|
|||
| Canonical SMILES |
CC(C)(C)N=C(NC#N)NC1=CC=CC(=C1)C(=CCCCC(=O)O)C2=CN=CC=C2
|
|||
| InChI |
1S/C23H27N5O2/c1-23(2,3)28-22(26-16-24)27-19-10-6-8-17(14-19)20(11-4-5-12-21(29)30)18-9-7-13-25-15-18/h6-11,13-15H,4-5,12H2,1-3H3,(H,29,30)(H2,26,27,28)/b20-11+
|
|||
| InChIKey |
XUTLOCQNGLJNSA-RGVLZGJSSA-N
|
|||
| CAS Number |
CAS 149979-74-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Thromboxane A2 receptor (TBXA2R) | Target Info | Antagonist | [2] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Platelet activation | ||||
| Reactome | Prostanoid ligand receptors | |||
| G alpha (q) signalling events | ||||
| G alpha (12/13) signalling events | ||||
| Thromboxane signalling through TP receptor | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Small Ligand GPCRs | ||||
| Signal amplification | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02223013) Relative Bioavailability and Tolerability of Two New Different Extended Release Capsules of BIBV 308 SE, Versus a Solution of BIBV 308 SE in Healthy Subjects. U.S. National Institutes of Health. | |||
| REF 2 | AT-1 receptor antagonism modifies the mediation of endothelin-1, thromboxane A2, and catecholamines in the renal constrictor response to angiotensin II. Kidney Int Suppl. 2005 Jan;(93):S3-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.